373 related articles for article (PubMed ID: 20667993)
1. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
[TBL] [Abstract][Full Text] [Related]
2. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade.
Chavez H; Beaudreuil S; Abbed K; Taoufic Y; Kriaa F; Charpentier B; Durrbach A
Transpl Immunol; 2007 Jun; 17(4):243-8. PubMed ID: 17493526
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.
van de Wetering J; Koumoutsakos P; Peeters A; van der Mast BJ; de Kuiper P; IJzermans JN; Weimar W; Baan CC
Clin Transplant; 2011; 25(1):40-6. PubMed ID: 20636406
[TBL] [Abstract][Full Text] [Related]
4. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Latek R; Fleener C; Lamian V; Kulbokas E; Davis PM; Suchard SJ; Curran M; Vincenti F; Townsend R
Transplantation; 2009 Mar; 87(6):926-33. PubMed ID: 19300198
[TBL] [Abstract][Full Text] [Related]
5. Decreased frequency of peripheral CD4(+) CD161(+) Th(17) -precursor cells in kidney transplant recipients on long-term therapy with Belatacept.
Vondran FW; Timrott K; Kollrich S; Klempnauer J; Schwinzer R; Becker T
Transpl Int; 2012 Apr; 25(4):455-63. PubMed ID: 22348376
[TBL] [Abstract][Full Text] [Related]
6. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment.
Furuzawa-Carballeda J; Lima G; Uribe-Uribe N; Avila-Casado C; Mancilla E; Morales-Buenrostro LE; Pérez-Garrido J; Pérez M; Cárdenas G; Llorente L; Alberú J
Transplant Proc; 2010 Nov; 42(9):3489-96. PubMed ID: 21094802
[TBL] [Abstract][Full Text] [Related]
7. T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
Riella LV; Sayegh MH
Expert Opin Biol Ther; 2013 Nov; 13(11):1557-68. PubMed ID: 24083381
[TBL] [Abstract][Full Text] [Related]
8. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model.
Wang S; Jiang J; Guan Q; Lan Z; Wang H; Nguan CY; Jevnikar AM; Du C
Transpl Immunol; 2008 May; 19(2):93-102. PubMed ID: 18503884
[TBL] [Abstract][Full Text] [Related]
10. Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells in kidney operational tolerance transplanted individuals.
Moraes-Vieira PM; Silva HM; Takenaka MC; Monteiro SM; Lemos F; Saitovitch D; Kalil J; Coelho V
Hum Immunol; 2010 May; 71(5):442-50. PubMed ID: 20122976
[TBL] [Abstract][Full Text] [Related]
11. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
Martin ST; Tichy EM; Gabardi S
Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
[TBL] [Abstract][Full Text] [Related]
12. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
Li Y; Shi Y; Huang Z; Bai Y; Niu Q; Cai B; Wang L; Feng W
Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083
[TBL] [Abstract][Full Text] [Related]
13. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.
Leibler C; Matignon M; Pilon C; Montespan F; Bigot J; Lang P; Carosella ED; Cohen J; Rouas-Freiss N; Grimbert P; Menier C
Am J Transplant; 2014 May; 14(5):1173-82. PubMed ID: 24730563
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
Noris M; Casiraghi F; Todeschini M; Cravedi P; Cugini D; Monteferrante G; Aiello S; Cassis L; Gotti E; Gaspari F; Cattaneo D; Perico N; Remuzzi G
J Am Soc Nephrol; 2007 Mar; 18(3):1007-18. PubMed ID: 17287424
[TBL] [Abstract][Full Text] [Related]
15. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
16. Foxp3+ T cells in peripheral blood of renal transplant recipients and clinical correlations.
Lin WX; Christiansen D; Fu LL; Roberts MA; Sandrin MS; Ierino FL
Nephrology (Carlton); 2012 May; 17(4):415-22. PubMed ID: 22308996
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation.
Guo L; Fujino M; Kimura H; Funeshima N; Kitazawa Y; Harihara Y; Tezuka K; Makuuchi M; Suzuki S; Li XK
Transpl Immunol; 2003; 12(1):41-8. PubMed ID: 14551031
[TBL] [Abstract][Full Text] [Related]
18. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.
Dummer CD; Carpio VN; Gonçalves LF; Manfro RC; Veronese FV
Transpl Immunol; 2012 Jan; 26(1):1-10. PubMed ID: 21939765
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
[TBL] [Abstract][Full Text] [Related]
20. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
